Company / Free Cash Flow
Fulgent Genetics, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$124.2M
FY2025
5-year range
-$124.2M / $514.8M
FY2021-FY2025
Trend
-545.1%
vs FY2024
Sector context
#144 of 151
Health Care
What the data says
Free Cash Flow changed -545% YoY in FY2025, a notable deviation from the 9-year average annual change of +619%.
Based on SEC 10-K filings.
-$124M in FY2025.
Declined from $515M to -$124M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 151This company -$124.2M Sector average $779.8M
▼
-115.9% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 545.1% year-over-year.
- Ranks #144 out of 151 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$124.2M | -545.1% |
| FY2024 | -$19.3M | -103.7% |
| FY2023 | $514.8M | +387.9% |
| FY2022 | $105.5M | +2333.6% |
| FY2021 | $4.3M | -95.9% |
| FY2020 | $105.5M | +3620.1% |
| FY2019 | -$3.0M | -91.6% |
| FY2018 | -$1.6M | +0.0% |
| FY2017 | -$1.6M | +69.5% |
| FY2016 | -$5.1M | -67.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026